WO2012032414A3 - Compositions comprenant un mélange d'huile constituée d'acides gras, un tensioactif et une statine - Google Patents
Compositions comprenant un mélange d'huile constituée d'acides gras, un tensioactif et une statine Download PDFInfo
- Publication number
- WO2012032414A3 WO2012032414A3 PCT/IB2011/002727 IB2011002727W WO2012032414A3 WO 2012032414 A3 WO2012032414 A3 WO 2012032414A3 IB 2011002727 W IB2011002727 W IB 2011002727W WO 2012032414 A3 WO2012032414 A3 WO 2012032414A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- statin
- surfactant
- fatty acid
- oil mixture
- acid oil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des préconcentrats comprenant un mélange d'huile constituée d'acides gras, au moins un tensioactif et au moins une statine ou un sel pharmaceutiquement acceptable, un hydrate, un solvate ou un complexe de celle-ci, ainsi que les utilisations de ces préconcentrats. Les préconcentrats peuvent former un système d'administration de médicament auto-nanoémulsifiant (SNEDDS), un système d'administration de médicament microémulsifiant (SMEDDS) ou des systèmes d'administration de médicament auto-émulsifiants (SEDDS) dans une solution aqueuse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38107010P | 2010-09-08 | 2010-09-08 | |
US61/381,070 | 2010-09-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012032414A2 WO2012032414A2 (fr) | 2012-03-15 |
WO2012032414A3 true WO2012032414A3 (fr) | 2012-05-03 |
Family
ID=45811014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/002727 WO2012032414A2 (fr) | 2010-09-08 | 2011-09-08 | Compositions comprenant un mélange d'huile constituée d'acides gras, un tensioactif et une statine |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR082930A1 (fr) |
WO (1) | WO2012032414A2 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3278665B1 (fr) | 2009-04-29 | 2020-09-09 | Amarin Pharmaceuticals Ireland Limited | Composition pharmaceutique stable et procédés d'utilisation associés |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
CN108096209A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ611606A (en) | 2010-11-29 | 2015-10-30 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
RU2633862C2 (ru) | 2012-03-30 | 2017-10-18 | Санчилио Энд Компани, Инк. | Композиции сложных эфиров омега-3 жирных кислот |
US10898458B2 (en) | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
US9480651B2 (en) | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
US20160228397A1 (en) | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
KR20150036252A (ko) | 2012-06-29 | 2015-04-07 | 애머린 파마슈티칼스 아일랜드 리미티드 | 스타틴 요법 중인 대상체에서 심혈관 사건의 위험을 감소시키는 방법 |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
CA2926335C (fr) | 2013-10-30 | 2021-11-23 | Banner Life Sciences Llc | Capsules enteriques molles comprenant des acides gras polyinsatures |
TR201403323A2 (tr) | 2014-03-21 | 2015-10-21 | Ege Ueniversitesi Bilim Teknoloji Uygulama Ve Arastirma Merkezi Ebiltem | Rosuvastatinin oral yolla kullanımı için kendiliğinden mikro/nano emülsifiye olabilen ilaç taşıyıcı sistemi. |
WO2015185240A1 (fr) * | 2014-06-04 | 2015-12-10 | Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. | Compositions contenant de la simvastatine dans des acides gras polyinsaturés oméga-3 |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US9895333B2 (en) | 2014-06-26 | 2018-02-20 | Patheon Softgels Inc. | Enhanced bioavailability of polyunsaturated fatty acids |
MA40846A (fr) * | 2014-10-10 | 2017-09-05 | Sancilio & Company Inc | Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques |
US20180015038A1 (en) * | 2015-01-21 | 2018-01-18 | Mochida Pharmaceutical Co., Ltd. | Omega-3 fatty acid self-emulsifying composition |
JP2019513802A (ja) * | 2016-04-14 | 2019-05-30 | ルシー マイケル | 組み合わせ組成物およびその使用方法 |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
EP3750536A1 (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ireland Limited | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5502077A (en) * | 1988-08-11 | 1996-03-26 | Norsk Hydro A.S. | Fatty acid composition |
WO1999029316A1 (fr) * | 1997-12-10 | 1999-06-17 | Severson, Mary, L. | Compositions pharmaceutiques contenant une huile d'acide gras omega-3 |
WO1999056727A2 (fr) * | 1998-05-07 | 1999-11-11 | Elan Corporation, Plc | Systemes d'apport de medicament de preconcentre de microemulsion et d'emulsion depourvues de solvant/cosolvant |
EP1157692A1 (fr) * | 2000-05-22 | 2001-11-28 | Quatex N.V. | Composition pharmaceutique d'acides gras, contenant au moins 80% en poids de EPA et DHA |
US20060034815A1 (en) * | 2004-08-06 | 2006-02-16 | Hector Guzman | Novel statin pharmaceutical compositions and related methods of treatment |
WO2006085144A2 (fr) * | 2004-10-15 | 2006-08-17 | Photonz Corporation Limited | Compositions contenant des niveaux eleves d'omega-3 et des niveaux faibles d'acides gras satures |
US20060211763A1 (en) * | 2005-03-08 | 2006-09-21 | Abdel Fawzy | Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof |
US20070141138A1 (en) * | 2005-12-20 | 2007-06-21 | Cenestra Llc | Omega 3 fatty acid formulations |
US20080085911A1 (en) * | 2006-10-10 | 2008-04-10 | Reliant Pharmaceuticals, Inc. | Statin and omega-3 fatty acids for reduction of apo-b levels |
WO2010103402A1 (fr) * | 2009-03-09 | 2010-09-16 | Pronova Biopharma Norge As | Compositions comprenant un mélange oléagineux à base d'acides gras comportant de l'epa et du dha sous forme d'acide libre et un tensioactif, et procédés et utilisations associés |
WO2011048493A1 (fr) * | 2009-10-23 | 2011-04-28 | Pronova Biopharma Norge As | Capsules ou comprimés enrobés d'un mélange oléagineux d'acides gras |
-
2011
- 2011-09-08 AR ARP110103282A patent/AR082930A1/es unknown
- 2011-09-08 WO PCT/IB2011/002727 patent/WO2012032414A2/fr active Application Filing
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5502077A (en) * | 1988-08-11 | 1996-03-26 | Norsk Hydro A.S. | Fatty acid composition |
WO1999029316A1 (fr) * | 1997-12-10 | 1999-06-17 | Severson, Mary, L. | Compositions pharmaceutiques contenant une huile d'acide gras omega-3 |
WO1999056727A2 (fr) * | 1998-05-07 | 1999-11-11 | Elan Corporation, Plc | Systemes d'apport de medicament de preconcentre de microemulsion et d'emulsion depourvues de solvant/cosolvant |
EP1157692A1 (fr) * | 2000-05-22 | 2001-11-28 | Quatex N.V. | Composition pharmaceutique d'acides gras, contenant au moins 80% en poids de EPA et DHA |
US20060034815A1 (en) * | 2004-08-06 | 2006-02-16 | Hector Guzman | Novel statin pharmaceutical compositions and related methods of treatment |
WO2006085144A2 (fr) * | 2004-10-15 | 2006-08-17 | Photonz Corporation Limited | Compositions contenant des niveaux eleves d'omega-3 et des niveaux faibles d'acides gras satures |
US20060211763A1 (en) * | 2005-03-08 | 2006-09-21 | Abdel Fawzy | Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof |
US20070141138A1 (en) * | 2005-12-20 | 2007-06-21 | Cenestra Llc | Omega 3 fatty acid formulations |
US20080085911A1 (en) * | 2006-10-10 | 2008-04-10 | Reliant Pharmaceuticals, Inc. | Statin and omega-3 fatty acids for reduction of apo-b levels |
WO2010103402A1 (fr) * | 2009-03-09 | 2010-09-16 | Pronova Biopharma Norge As | Compositions comprenant un mélange oléagineux à base d'acides gras comportant de l'epa et du dha sous forme d'acide libre et un tensioactif, et procédés et utilisations associés |
WO2010103404A1 (fr) * | 2009-03-09 | 2010-09-16 | Pronova Biopharma Norge As | Compositions comprenant un mélange d'huile d'acide gras et d'agent tensio-actif, et leurs procédés et utilisations |
WO2010119319A1 (fr) * | 2009-03-09 | 2010-10-21 | Pronova Biopharma Norge As | Compositions comprenant un mélange oléagineux à base d'acides gras et d'un acide gras libre, et procédés et utilisations associés |
WO2011048493A1 (fr) * | 2009-10-23 | 2011-04-28 | Pronova Biopharma Norge As | Capsules ou comprimés enrobés d'un mélange oléagineux d'acides gras |
Also Published As
Publication number | Publication date |
---|---|
WO2012032414A2 (fr) | 2012-03-15 |
AR082930A1 (es) | 2013-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012032414A3 (fr) | Compositions comprenant un mélange d'huile constituée d'acides gras, un tensioactif et une statine | |
WO2012032415A3 (fr) | Compositions comprenant un mélange d'huile constituée d'acides gras comprenant epa et dha sous forme d'acide libre, un tensioactif et une statine | |
WO2012032417A3 (fr) | Compositions comprenant un mélange d'huiles d'acides gras, un acide gras libre et une statine | |
IL180597A0 (en) | Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility | |
WO2012021715A3 (fr) | Formulations stables de linaclotide | |
PH12019500030A1 (en) | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof | |
IN2014MN02213A (fr) | ||
WO2009085990A3 (fr) | Procédés de préparation de sitagliptine et sels pharmaceutiquement acceptables de celle-ci | |
DE602007013611D1 (fr) | ||
TW200744665A (en) | Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof | |
WO2011041694A3 (fr) | Composés utiles comme antagonistes du récepteur de l'acide lysophosphatidique (lpa) | |
WO2011017350A3 (fr) | Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique | |
WO2011080148A3 (fr) | Nanosuspension intraveineuse aqueuse ayant des effets indésirables réduits | |
NZ748572A (en) | Pharmaceutical compositions having improved storage stability | |
WO2010070449A3 (fr) | Laquinimode très pur ou sel pharmaceutiquement acceptable de celui-ci | |
PL2046292T3 (pl) | Preparaty eterów benzymidazolilo-pirydylowych | |
WO2011019326A3 (fr) | Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité | |
WO2009060952A1 (fr) | Nouvelle préparation | |
WO2008001201A3 (fr) | Compositions pharmaceutiques de clopidogrel | |
MX2012001691A (es) | Composiciones de linaclotida que se desintegran oralmente. | |
JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
WO2010148314A3 (fr) | Préparation d'ésoméprazole et de ses sels pharmaceutiquement acceptables | |
WO2012054093A3 (fr) | Inhibiteurs d'acyl pipéridine d'époxyde hydrolase soluble | |
WO2011103920A3 (fr) | Formule pharmaceutique ou nutraceutique | |
WO2011100838A8 (fr) | Dérivés de 1-phényl-1,5-dihydro-benzo[b] [1.4]diazépine-2.4-dione en tant qu'inhibiteurs de la réplication du vih |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11823129 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11823129 Country of ref document: EP Kind code of ref document: A2 |